Vaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedLoading investors…
Activity from announced rounds
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
Develops treatments for chronic lung diseases, focusing on viral respiratory infections
Pitching Medicxi? Send the deck from a free RoundOS data room and see which pages they read.
Create a free room